Advertisement

Adjuvante Chemotherapie beim operablen Mammakarzinom

  • H. J. Senn
Conference paper

Zusammenfassung

Die Heilungschancen von Patientinnen mit „radikal operablem Mammakarzinom“ haben sich im Laufe der letzten Jahrzehnte ungeachtet der variablen Radikalität des chirurgischen Primäreingriffs sowie prä- bzw. postoperativer adjuvanter Radiotherapie nicht nennenswert verbessert [2, 4, 17, 49, 57, 61]. Es ist eine ernüchternde, aber auch therapeutisch heilsame Feststellung, daß die kurativen Möglichkeiten der alleinigen loko-regionären Primärtherapie die kurativen Aussichten des häufigsten Tumorleidens unserer Frauen in den westlichen Industrieländern kaum mehr verbessern können, wenn auch bezüglich Verminderung der chirurgischen und aktinischen Langzeitfolgen mit ihren kosmetischen Auswirkungen noch einiges zu tun bleibt. Abbildung 1 zeigt die Entwicklung der altersspezifischen Mortalität an Brustkrebs in der Schweiz zwischen 1900–1960. Die langsame, leichte Zunahme der Inzidenz ist (vor allem in den höheren Altersstufen) auch mit einer leicht ansteigenden Mortalität vergesellschaftet [58]. Nach Erhebungen des National Cancer Institut der USA scheint die Mortalität an Brustkrebs bei Frauen unter 45 Jahren neuerdings merklich abzunehmen [16].

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Allen H, Brooks R, Jones SE et al. (1981) Adjuvant treatment for stage II breast cancer with adriamycin and cyclophosphamide. Adjuvant therapy of cancer III, Grune & Stratton, New York, p. 453Google Scholar
  2. 2.
    Baum M (1976) The curability of breast cancer. Brit Med J. I: 439CrossRefGoogle Scholar
  3. 3.
    Baum M, Berstock D (1982) Breast cancer adjuvant therapy. Clinics in Oncology. 1: 901Google Scholar
  4. 4.
    Bonadonna G, Valagussa P, Rossi A et al. (1978) Are surgical adjuvant trials going to alter the course of breast cancer? Seminars of Oncol. 5: 450Google Scholar
  5. 5.
    Bonadonna G, Valagussa P (1981) Dose response effect of adjuvant chemotherapy in breast cancer. N Engl J Med. 304: 10PubMedCrossRefGoogle Scholar
  6. 6.
    Bonadonna G, Valagussa P (1982) Adjuvant therapy of primary breast cancer, in Carter SK, Glatstein E, Livingstone RB (eds). Principles of cancer treatment, New York, p. 315Google Scholar
  7. 7.
    Brinkley D, Haybittle JL (1975) The curability of breast cancer. Lancet. II: 95Google Scholar
  8. 8.
    Brunner KW, Sonntag RW, Martz G et al. (1975) Controlled study of the use of combined drug therapy for metastatic breast cancer. Cancer. 36: 1208PubMedCrossRefGoogle Scholar
  9. 9.
    Buzdar AU, Blumenschein GR, Hortobagyi GN, Yap HY (1980) 5 years follow up of FACBCG adjuvant therapy of stage II+III breast cancer. Cancer Chemother Pharm. 5: 8Google Scholar
  10. 10.
    Casiato DA, Scott JL (1979) Acute leukemia following prolonged cytotoxic agent therapy. Medicine (Baltimore). 58: 32CrossRefGoogle Scholar
  11. 11.
    Cavalli F, Pedrazzini A, Martz G et al. (1983) Randomized trial of 3 different regimes of combined chemotherapy in patients receiving simultaneous hormonal treatment for advanced breast cancer. Europ J Cancer. 19: 1615CrossRefGoogle Scholar
  12. 12.
    Cooper MR, Rhyne AL, Muss HB et al. (1981) A randomized comparative trial of chemotherapy and irradiation therapy for stage 2 breast cancer. Cancer. 47: 2833PubMedCrossRefGoogle Scholar
  13. 13.
    Cooper RG, Holland JF, Glidewell O (1979) Adjuvant chemotherapy for breast cancer. Cancer. 44: 793PubMedCrossRefGoogle Scholar
  14. 14.
    Cutter SJ, Myers MH, Green SB (1975) Trends in survival rates in patients with cancer. N Engl J Med. 293: 122CrossRefGoogle Scholar
  15. 15.
    Davis HL, Metter GE, Ramirez G et al. (1979) An adjuvant trial of L-PAM versus CMF-V following mastectomy for operable breast cancer. Proc ASCO. 20: 358Google Scholar
  16. 16.
    De Vita V Jr. (1981) Recent perspectives on the development of drug resistance and some more good news, in Salmon SE, Jones SE (eds) Adjuvant therapy of cancer III, Grune & Stratton, New York, p. 3Google Scholar
  17. 17.
    Fisher B, Slack NH, Ravdin RG et al. (1968) Surgical adjuvant chemotherapy in cancer of the breast. Results of a decade of cooperative investigation. Ann Surg. 168: 337PubMedCrossRefGoogle Scholar
  18. 18.
    Fisher B, Slack NH, Cavanaught PJ et al. (1970) Postoperative radiotherapy in the treatment of breast cancer: results of an NSABP trial. Ann Surg. 172: 711PubMedCrossRefGoogle Scholar
  19. 19.
    Fisher B (1977) Biological and clinical considerations regarding the use of surgery and chemotherapy in the treatment of primary breast cancer. Cancer. 40: 574PubMedCrossRefGoogle Scholar
  20. 20.
    Fisher B (1979) Breast cancer management — alternatives to mastectomy. N Engl J Med 301: 326PubMedCrossRefGoogle Scholar
  21. 21.
    Fisher B (1980) Laboratory and clinical research in breast cancer — a personal adventure. Cancer Res. 40: 3863PubMedGoogle Scholar
  22. 22.
    Fisher B, Redmond C, Brown A et al. (1981) Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl Med J. 305: 1CrossRefGoogle Scholar
  23. 23.
    Frey U, Senn HJ (1978) Nachweis ossärer Tumormetastasen. Schweiz Med Wschr. 108: 82PubMedGoogle Scholar
  24. 24.
    Glucksberg H, Rivkin SE, Rasmussen S et al. (1982) CMFVP versus L-PAM for operable breast cancer with positive axillary nodes. A Southwest Oncology Group Study. Cancer. 50: 423PubMedCrossRefGoogle Scholar
  25. 25.
    Goldhirsch A and Ludwig Breast Cancer Study Group (1983) Personal communicationGoogle Scholar
  26. 26.
    Haybittle JL (1983) Is breast cancer ever cured? Reviews on endocrine related cancer. 14: 13Google Scholar
  27. 27.
    Henderson JC, Gelman R, Parker LM et al. (1982) 15 versus 30 weeks of adjuvant chemotherapy of breast cancer patients with high risk of recurrence. Proc ASCO. 1: 75Google Scholar
  28. 28.
    Holdener EE, Osterwalder J, Senn HJ (1982) Zweitmalignome bei operiertem Mammakarzinom: Vergleich retrospektiver and prospektiver Erfahrungen. Schweiz Med Wschr. 112: 1800PubMedGoogle Scholar
  29. 29.
    Holland JF (1976) Major advance in breast cancer therapy. N Engl J Med. 294: 440PubMedCrossRefGoogle Scholar
  30. 30.
    Jones SE (1983) Personal communicationGoogle Scholar
  31. 31.
    Jungi WF, Alberto P, Brunner KW et al. (1981) Short or longterm adjuvant chemotherapy for breast cancer. Adjuvant therapy of cancer III, Grune & Stratton, New York, p. 395Google Scholar
  32. 32.
    Kardinal SG, Donegan WL (1980) Second cancers after prolonged adjuvant Thio-Tepa for operable breast cancer. Cancer 45: 2042PubMedCrossRefGoogle Scholar
  33. 33.
    Ludwig Breast Cancer Study Group (1983) Toxic effects of early adjuvant chemotherapy for breast cancer. Lancet II: 542Google Scholar
  34. 34.
    Ludwig Breast Cancer Study Group (1983) Unpublished dataGoogle Scholar
  35. 35.
    Meaking JW, Allt FA, Beale TC et al. (1977) Ovarian irradiation and prednisone following surgery for carcinoma of the breast. Adjuvant therapy of cancer I, Elsevier, Amsterdam, p. 95Google Scholar
  36. 36.
    Merlin C, Gloor F, Hardmeier T, Senn HJ (1980) Hat die intramammäre Lymphangiosis carcinomatosa eine prognostische Bedeutung beim nodal-negativen Mammakarzinom? Schweiz Med Wschr. 110: 605PubMedGoogle Scholar
  37. 37.
    Nime FA, Rosen TP, Thaler H et al. (1977) Prognostic significance of tumor cell emboli in intramammary lymphatics in patients with mammary carcinomas. Ann Surg Path 1: 25CrossRefGoogle Scholar
  38. 38.
    Nissen-Meyer R, Kjellgren K, Mansson B (1982) Adjuvant chemotherapy in breast cancer. Recent Results Cancer Res 80: 142PubMedGoogle Scholar
  39. 39.
    Palshof T, Mouridsen HT, Daehnfeldt JL (1983) Report on the Copenhagen breast cancer trials; adjuvant endocrine therapy of primary operable breast cancer. Breast cancer — experimental and clinical aspects, Pergamon Press, Oxford, p. 119Google Scholar
  40. 40.
    Ribeiro G, Palmer K (1983) Adjuvant tamoxifen for operable carcinoma of the breast; report of clinical trial by the Christie Hospital and Holt Radium Institute. Br Med J 286: 827CrossRefGoogle Scholar
  41. 41.
    Rose C, Thorpe SM, Mouridsen HT et al. (1983) Antiestrogen treatment of postmenopausal women with primary high risk breast cancer. Breast Cancer Res Treat 3: 77PubMedCrossRefGoogle Scholar
  42. 42.
    Rosner F, Grunwald H (1975) Hodgkin’s disease and acute leukemia. Am J Med 57: 927CrossRefGoogle Scholar
  43. 43.
    Rosner F, Carey RW (1978) Breast cancer and acute leukemia. Am J Haematol 4: 151CrossRefGoogle Scholar
  44. 44.
    Rossi A, Bonadonna G, Valagussa P, Veronesi U (1981) Multimodal treatment in operable breast cancer: 5 year results of the CMF program. Br J Med 282: 1427CrossRefGoogle Scholar
  45. 45.
    Schabel FM (1975) Concept for systemic treatment of micrometastases. Cancer 35: 15PubMedCrossRefGoogle Scholar
  46. 46.
    Schabel FM (1977) Surgical adjuvant chemotherapy of metastatic murine tumors. Cancer 40: 558PubMedCrossRefGoogle Scholar
  47. 47.
    Senn HJ, Mayr AC (1979) Adjuvant chemotherapy in breast cancer — Swiss cooperative studies. Cancer Treat Rev (Suppl) 6: 79CrossRefGoogle Scholar
  48. 48.
    Senn HJ, Amgwerd R, Jungi WF et al. (1981) Adjuvant chemo-immunotherapy with LMF and BCG in node-negative and node-positive breast cancer; 5 year results. Adjuvant therapy of cancer III, Grune & Stratton, New York, p. 385Google Scholar
  49. 49.
    Senn HJ (1982) Current status and indications for adjuvant chemotherapy in breast cancer. Cancer Chemother Pharmacol 8: 139PubMedCrossRefGoogle Scholar
  50. 50.
    Skipper HE (1978) Adjuvant chemotherapy. Cancer 42: 936CrossRefGoogle Scholar
  51. 51.
    Sutow WW, Sullivan MP (1976) Childhood cancer — the improving prognosis. Postgrad Med 59: 131PubMedGoogle Scholar
  52. 52.
    Tancini G, Bonadonna G, Valagussa P et al. (1983) Adjuvant CMF in breast cancer: comparative 5 year results of 12 cycles versus 6 cycles. J Clin Oncol 1: 2PubMedGoogle Scholar
  53. 53.
    Tormey DC (1975) Combined surgery and chemotherapy in breast cancer — a review. Cancer 36: 881PubMedCrossRefGoogle Scholar
  54. 54.
    Tormey DC, Weinberg VE, Holland JF et al. (1983) A randomized trial of 5 and3 drug chemotherapy and chemoimmunotherapy in women with operable node positive breast cancer. J Clin Oncol 1: 138PubMedGoogle Scholar
  55. 55.
    Tormey DC, Kalish L, Cummings FJ, Carbone P (1983) Premenopausal breast cancer adjuvant chemotherapy — the ECOG trial. Proc ASCO 2: 102Google Scholar
  56. 56.
    Trask C, Souhami R (1982) Multimodal treatment in operable breast cancer. Br Med J 282: 1571Google Scholar
  57. 57.
    Valagussa P, Bonadonna G, Veronesi U (1978) Patterns of relapse and survival following radical mastectomy. Cancer 41: 1170PubMedCrossRefGoogle Scholar
  58. 58.
    Van der Linde F (1977) Definition der Bevölkerungsgruppen mit hohem Risiko beim Mammakarzinom. Schweiz Med Wschr 107: 962PubMedGoogle Scholar
  59. 59.
    Velez-Garcia E, Moore M, Marcid V et al. (1983) Postoperative adjuvant chemotherapy with or without radiation in patients with stage II breast cancer — a SECSG study. Proc ASCO 2: 111Google Scholar
  60. 60.
    Veronesi U, Costa A, Grandi C (1977) Surgical treatment of primary breast cancer. Schweiz Med Wschr 107: 987PubMedGoogle Scholar
  61. 61.
    Young RC, Lippman M, De Vita VT et al. (1977) Perspectives in the treatment of breast cancer. Ann Int Med 86: 784Google Scholar

Nachtrag zum Literaturverzeichnis

  1. 1a.
    Ahmann DL, Payne WS, Scanlon PW et al. (1978) Repeated adjuvant chemotherapy with phenylalanin mustard or 5 fluorouracil, cyclophosphamide and prednisone with or without radiation, after mastectomy for breast cancer. Lancet I: 893Google Scholar
  2. 29a.
    Howat IMT, Hughes R, Durning P et al. (1981) A controlled clinical trial of adjuvant chemotherapy in operable cancer of the breast. Adjuvant therapy of cancer III, Grune & Stratton, New York, p. 371Google Scholar
  3. 39a.
    Pritschard KI, Meakin JW, Boyd NF et al. (1983) A prospective randomized controlled trial of adjuvant tamoxifen in postmenopausal women with axillary node positive breast cancer. Proc ASCO 2: 104Google Scholar
  4. 44a.
    Rubens RD, Hayward JL, Knight RK et al. (1983) Controlled trial of adjuvant chemotherapy with melphalan for breast cancer. Lancet I: 839Google Scholar
  5. 44b.
    Sauter Chr (1983) Hat die heutige adjuvante zytostatische Chemotherapie bei radikal operierten Mammakarzinompatientinnen versagt? Schweiz Med Wschr 113: 414PubMedGoogle Scholar

Copyright information

© Springer: Berlin Heidelberg 1985

Authors and Affiliations

  • H. J. Senn

There are no affiliations available

Personalised recommendations